Strategic Planning for Biotechnology

To perform an early phase feasibility analysis in order to identify the key clinical and economic issues for a successful launch of pharmaceutical, device or nutrition in the key markets, including clinica, health economic  and legal hurdles.

To create the overall strategy for pricing and reimbursement ensuring that the position is consistent with US and European markets, including optimal positioning and pricing, cost-effectiveness and equity criteria.

To develop value proposition for payers in each country as part of the planning activities, including the need for cost-effectiveness outcomes.

Cosensus panels: Organisation of a working meeting with a panel of international experts. The aim is to generate guidance on a specific topic in health care policy, including health economics, but also other criteria like social values and equity.  

Clinical and economic issues complicating cost-effectiveness evaluation of orphan diseases. The EuroBiotech Journal, 2017, Vol.1(2), p. 1-10.

Mark J.C. Nuijten.  Early phase value scan for biotechnology innovation. Vol 1. May 2017: 159-164.

Nuijten MJC, Vis J. J valuation and valuation of innovative medicinal products. Rare Dis Res Treat. (2016) 2(1): 1-11

MJ Nuijten, J Vis. The Evaluation of Innovative Drugs Applying Business Valuation Concepts. Value in Health. 2016: November; 18.A504.